Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03233347
Title Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Mayo Clinic in Rochester Rochester Minnesota 55905 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Carolinas Medical Center/Levine Cancer Institute Charlotte North Carolina 28203 United States Details
University of Pennsylvania/Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
University of Washington Medical Center - Montlake Seattle Washington 98195 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field